PMID- 26511677
OWN - NLM
STAT- MEDLINE
DCOM- 20160803
LR  - 20160322
IS  - 1531-4995 (Electronic)
IS  - 0023-852X (Linking)
VI  - 126
IP  - 4
DP  - 2016 Apr
TI  - The prognostic role of E-cadherin and beta-catenin overexpression in laryngeal 
      squamous cell carcinoma.
PG  - E148-55
LID - 10.1002/lary.25736 [doi]
AB  - OBJECTIVES/HYPOTHESIS: Epithelial-to-mesenchymal transition (EMT) consists of a 
      rapid and reversible change in the cellular phenotype toward the mesenchymal cell 
      phenotype that facilitates cell migration and invasion of the tumor into 
      surrounding tissues followed by metastasis. In the present study, we sought to 
      determine the clinical significance of E-cadherin, N-cadherin, beta-catenin, 
      alpha-catenin, gamma-catenin, caveolin-1, and vimentin in a cohort of patients with stage 
      I to IVA laryngeal squamous cell carcinoma (LSCC) treated with surgery with or 
      without adjuvant therapy using immunohistochemical analyses. STUDY DESIGN: 
      Individual retrospective cohort study. METHODS: E-cadherin, N-cadherin, 
      beta-catenin, alpha-catenin, gamma-catenin, caveolin-1, and vimentin immunohistochemical 
      expression were evaluated in a cohort of 82 patients with stages I to IVA LSCC. 
      The Fisher exact test was used for categorical variables, and the Mann-Whitney 
      test where appropriate for continuous variables. Survival comparisons was 
      performed using the log-rank test. A multivariate analysis using the Cox 
      proportional hazards model was performed and considered all EMT markers. RESULTS: 
      In multivariate analysis, T stage was an independent risk factor for adverse 
      disease-specific survival (DSS) and overall survival (OS) (P = .025 and .019, 
      respectively). Cytoplasmic beta-catenin overexpression was independently associated 
      with a longer DSS (P = .0007), and E-cadherin overexpression was found to be an 
      independent risk factor for poor OS (P = .030). CONCLUSIONS: E-cadherin and 
      beta-catenin pathways could represent future therapeutic targets in the treatment of 
      LSCC. However, validation of our results in prospective cohorts of patients with 
      LSCCs is required before their clinical implementation. LEVEL OF EVIDENCE: NA.
CI  - (c) 2015 The American Laryngological, Rhinological and Otological Society, Inc.
FAU - Greco, Antonio
AU  - Greco A
AD  - Department Organs of Sense, ENT Section, "Sapienza" University of Rome, Rome, 
      Italy.
FAU - De Virgilio, Armando
AU  - De Virgilio A
AD  - Department Organs of Sense, ENT Section, "Sapienza" University of Rome, Rome, 
      Italy.
AD  - Department of Surgical Science, "Sapienza" University of Rome, Rome, Italy.
FAU - Rizzo, Maria Ida
AU  - Rizzo MI
AD  - Department of Surgical Science, "Sapienza" University of Rome, Rome, Italy.
FAU - Pandolfi, Fabio
AU  - Pandolfi F
AD  - Department Organs of Sense, ENT Section, "Sapienza" University of Rome, Rome, 
      Italy.
FAU - Rosati, Davide
AU  - Rosati D
AD  - Department Organs of Sense, ENT Section, "Sapienza" University of Rome, Rome, 
      Italy.
FAU - de Vincentiis, Marco
AU  - de Vincentiis M
AD  - Department Organs of Sense, ENT Section, "Sapienza" University of Rome, Rome, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151029
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - 0 (Cadherins)
RN  - 0 (beta Catenin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cadherins/*biosynthesis/genetics
MH  - Carcinoma, Squamous Cell/genetics/*metabolism
MH  - Cohort Studies
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - beta Catenin/*biosynthesis/genetics
OTO - NOTNLM
OT  - E-cadherin
OT  - caveolin-1
OT  - epithelial-to-mesenchymal transition
OT  - larynx carcinoma
OT  - beta-catenin
EDAT- 2015/10/30 06:00
MHDA- 2016/08/04 06:00
CRDT- 2015/10/30 06:00
PHST- 2015/06/16 00:00 [received]
PHST- 2015/09/09 00:00 [revised]
PHST- 2015/09/22 00:00 [accepted]
PHST- 2015/10/30 06:00 [entrez]
PHST- 2015/10/30 06:00 [pubmed]
PHST- 2016/08/04 06:00 [medline]
AID - 10.1002/lary.25736 [doi]
PST - ppublish
SO  - Laryngoscope. 2016 Apr;126(4):E148-55. doi: 10.1002/lary.25736. Epub 2015 Oct 29.